Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Asian, Multicenter, Randomized, Double-blind, Placebo-controlled, 14-week Study of Mirogabalin in Participants With Central Neuropathic Pain Followed by a 52-week, Open-label Extension

Next Previous
Search
Trial Profile

An Asian, Multicenter, Randomized, Double-blind, Placebo-controlled, 14-week Study of Mirogabalin in Participants With Central Neuropathic Pain Followed by a 52-week, Open-label Extension

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mirogabalin (Primary)
  • Indications Neuropathic pain
  • Focus Registrational; Therapeutic Use
  • Acronyms AMELA
  • Sponsors Daiichi Sankyo Company

    • Most Recent Events

    • 28 Apr 2023 Results from open label part, published in the Pain and Therapy
    • 14 Dec 2022 Results published in the Neurology
    • 28 Mar 2022 According to a Daiichi Sankyo Company media release, the company obtained approval in Japan to change the indication of the analgesic "Tarlige Tablets" (mirogabalin besilate) from "peripheral neuropathic pain" to "neuropathic pain."

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top